Altimmune Advances to Phase 3 in MASH Following Previous Trial Setback
Altimmune has announced its advancement to Phase 3 trials for pemvidutide, a GLP-1/glucagon agonist aimed…
Newswire
MHRA Approves Lenacapavir for the Prevention of Sexually Transmitted HIV-1 Infection
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for lenacapavir, marking…
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions aimed at lowering prescription drug…
Nxera Seeks Schizophrenia Programme Buyer After Boehringer Snub
Shares in Tokyo-listed Nxera Pharma slid 5% at market open following Boehringer Ingelheim’s decision to…
Filovirus Detection by Immune System Improved by Nanoparticle Vaccine
Researchers at Scripps Research have developed a novel nanoparticle vaccine that enhances the immune system’s…
Galapagos TYK2 Drug Achieves Success in Dermatology Trial but Falls Short in Lupus Study
The Belgian biotech Galapagos has reported mixed results for its TYK2 inhibitor, GLPG3667, achieving success…
AI and Gene Therapy Lead 2025’s Most Impactful Pharma Stories
In a year marked by significant advancements, the final episode of 2025 from the GEN…
Aditum Bio Partners with Fosun for Significant Biopharmaceutical Collaboration
Aditum Bio, the biotech firm co-founded by former Novartis executives Joe Jimenez and Mark Fishman,…
Emer Cooke, EMA’s Executive Director: 2025 Achievements in Medicine Regulation
In 2025, the European Medicines Agency (EMA) marked significant advancements in the regulation of pharmaceuticals,…
AstraZeneca to Withdraw Andexxa Following FDA Risk Assessment
AstraZeneca is set to withdraw its bleeding reversal agent Andexxa from the market in the…